Remarkably, a good efficacy of this inhibitor was observed in NSCLC devoid of PIK3CA gene mutations, but with constitutive activation of the PI3K/AKT pathway in vitro and in vivo. The gene discussed is PIK3CG; the disease is non-small cell lung carcinoma.